Biophotonics is the combination of photonics and biology and is a multidisciplinary research field embracing all light-based technologies applied to life sciences and medicine. It is used to examine, control, and track biological processes at various levels of biology: cellular, tissue, molecular, and organism level. The biophotonics market consists of revenues generated from the sales of biophotonic instruments combining optics, nanotechnology, photonics, and biotechnology. Biophotonics is the combination of photonics and biology and is a multidisciplinary research field embracing all light-based technologies applied to life sciences and medicine. It refers to the use of photonic or optical means to examine, control, and track biological processes at various levels of biology: cellular, tissue, molecular, and organism level. The main product technologies in biophotonics are in-vitro and in-vivo. In vitro studies examine microorganisms, cells, and biological molecules outside of their natural biological framework. These studies in biology and its subdisciplines are generally done in labware such as test tubes, flasks, Petri dishes, and microtiter plates, and are referred to as test-tube investigations. The different applications include see-through imaging, inside imaging, spectromolecular, surface imaging, microscopy, light therapy, biosensors, and others and are used by various sectors such as diagnostics, therapeutic, tests, and others. The biophotonics market research report is one of a series of new reports from The Business Research Company that provides biophotonics market statistics, including biophotonics industry global market size, regional shares, competitors with a biophotonics market share, detailed biophotonics market segments, market trends and opportunities, and any further data you may need to thrive in the biophotonics industry. This biophotonics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global biophotonics market size will grow from $67.04 billion in 2022 to $74.38 billion in 2023 at a compound annual growth rate (CAGR) of 10.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global biophotonics market size is expected to grow to $113.99 billion in 2027 at a CAGR of 11.3%. The increasing demand for minimally invasive surgeries is contributing to the growth of the biophotonics market. Optical engineering and imaging technologies are playing a vital role in the evolving field of minimally invasive surgeries by enabling to visualize the manipulation of tissue at remote internal sites. According to a report by Intuitive Surgical, Inc., a US-based company specializing in minimally invasive care and the pioneer of robotic-assisted surgery, stated that they performed 10 million surgeries in 2021. Therefore, the surge in the number of minimally invasive surgeries annually worldwide is generating higher revenues for the biophotonics market. High prices of biophotonic-based devices or instruments are anticipated to limit the growth of the biophotonics market. The price of biophotonics is comparatively higher than that of conventional instruments. They are considered as more complex attributing to the integration of biological units and the generation, manipulation, and detection of light units, thereby rising their price. This will negatively impact the biophotonics market growth. The launch of new advanced techniques in the field of biotechnology is a major trend shaping the biophotonics market. For instance, a team of scientists at the University of St. Andrews (Scotland) developed a fluorescence microscopy technique that allows imaging of delicate biological samples with low damage in neuroscience and biomedicine. This low-damage optical technique is projected to transform the world of biomedicine in the forthcoming years. Hence, the development of new and advanced techniques is gaining significant popularity in the biophotonics market. In April 2021, CellaVision, a Sweden based company that offers digital Morphology Solutions acquired exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy from Clearbridge BioPhotonics for $3.28 million (SEK 28.7 million). Through this acquisition, CellaVision will have access to and control over a promising future technology. CellaVision believes that the Fourier Ptychography Microscopy technology has the capability to be employed in the development of future automated microscopes for use in haematology and related fields. Clearbridge Biophotonics, Inc. is a US-based imaging solutions company. Major players in the biophotonics market are Thermo Fisher Scientific, OPGEN, NU Skin Enterprises, IPG Photonics Corp., Idex Corp., Toshiba, Procter & Gamble, Horiba and Precision Photonics Corp. North America was the largest region in the biophotonics market in 2022. Western Europe was the second largest region in the global biophotonics market. The regions covered in the global biophotonics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The biophotonics market includes revenue earned by systems, technologies, and instruments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global biophotonics market is segmented - 1) By Product Technology: In-Vitro, In-Vivo 2) By Application: See-Through Imaging, Inside Imaging, Spectromolecular, Surface Imaging, Microscopy, Light Therapy, Biosensors, Other Applications 3) By End Use: Diagnostics, Therapeutic, Tests, Other End Uses

The biopsy devices are used to extract sample cells or tissues from the patient's body to be examined to determine the presence of a disease. The main product types in biopsy devices are needle-based biopsy instruments, core biopsy devices, aspiration biopsy needles, vacuum-assisted biopsy devices, biopsy forceps, and localization wires. The core biopsy devices utilize a large hollow needle to make a small incision in the skin over the lump. The various imaging technologies included are MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, and CT scan. The applications included in this market are breast biopsy, gynecological biopsy, prostate biopsy, liver biopsy, lung biopsy, kidney biopsy, gastroenterology biopsy, and others that are used in diagnostics and imaging centers, hospitals, and others. The biopsy devices market research report is one of a series of new reports from The Business Research Company that provides biopsy devices market statistics, including biopsy devices industry global market size, regional shares, competitors with a biopsy devices market share, detailed biopsy devices market segments, market trends and opportunities, and any further data you may need to thrive in the biopsy devices industry. This biopsy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global biopsy devices market grew from $2.64 billion in 2022 to $2.86 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biopsy devices market is expected to grow from $3.83 billion in 2027 at a CAGR of 7.6%. The rise in the number of cancer cases contributed to the growth of the biopsy devices market. A biopsy is a primary approach used by doctors to diagnose any abnormalities in the bodies if the presence of cancer cells is suspected. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The rise in complications associated with biopsies is expected to limit the growth of the biopsy devices market. Complications resulting from a biopsy include excessive bleeding, infection, puncture damage to nearby organ tissue, and skin numbness around the biopsy site. In some cases, not enough materials are collected, and the process needs to be repeated. According to research published in January 2020, major bleeding after percutaneous native kidney biopsy was around 4.3%. These complications in biopsy procedures impact the market's growth. Robot-assisted biopsy systems are shaping the biopsy devices market and help avoid complications after the biopsy. The robot-assisted biopsy is done to increase the precision and accuracy of the biopsy process and medical authorities have been approving the devices to make the process easier. For instance, in July 2022, the FDA cleared Siemens Healthineers’ and Intuitive’s platforms to make a robotic-assisted platform for minimally invasive lung biopsies. The integration would allow 2D and 3D imaging during procedures. In February 2020, MEDTRONIC PLC., a US-based medical device company, acquired Digital Surgery for an undisclosed amount. The acquisition would strengthen Medtronic’s robot-assisted surgical platform and broaden its portfolio. Digital Surgery is a London-based company in surgical artificial intelligence and robot-assisted surgery. Major players in the biopsy devices market are Becton Dickinson and Company (BD), Cook Medical, Argon Medical Devices, Hologic, Boston Scientific Corporation, Cardinal Health, B. Braun Melsungen AG, Medtronic, Devicor Medical Products, and Danaher Corporation (Leica Microsystem). North America was the largest region in the biopsy devices market in 2022. Asia-Pacific was the second largest region in the global biopsy devices market report. The regions covered in the global biopsy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biopsy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The biopsy devices market consists of sales of core biopsy guns, core biopsy needles, aspiration biopsy needles, vacuum-assisted biopsy systems, vacuum-assisted biopsy needles, localization wires, procedure trays, and other biopsy devices that are used to diagnose various diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global biopsy devices market is segmented - 1) By Product Type: Needle-Based Biopsy Instruments, Core Biopsy Devices, Aspiration Biopsy Needles, Vacuum-Assisted Biopsy Devices, Biopsy Forceps, Localization Wires 2) By Imaging Technology: MRI-guided biopsy, Stereotactic-guided biopsy, Ultrasound-guided biopsy, CT scan. 3) By Application: Breast Biopsy, Gynecological Biopsy, Prostate biopsy, Liver biopsy, Lung biopsy, Kidney biopsy, Gastroenterology biopsy, Other Applications 4) By End User: Diagnostics & Imaging Centers, Hospitals, Other End Users

Ultrasound systems are machines used to see internal body structures based on the ultrasound application. Ultrasound systems are used in applications such as radiology/general imaging, orthopedic, cardiology, obstetrics/gynecology, vascular, urology, and other applications (breast imaging, hematology, anesthesiology, and emergency care). The main types in the ultrasound devices and equipment are diagnostic ultrasound systems and therapeutic ultrasound systems. Internal organs are examined using diagnostic ultrasound systems. The various products are A-Mode, B-Mode or 2D Mode, C-Mode, M-Mode, Doppler mode, pulse inversion mode, and harmonic mode. These are used by hospitals, diagnostic imaging and surgical centres, ambulatory surgical centres (ASCs), and clinics. The ultrasound devices and equipment market research report is one of a series of new reports from The Business Research Company that provides ultrasound devices and equipment market statistics, including ultrasound devices and equipment industry global market size, regional shares, competitors with a ultrasound devices and equipment market share, detailed ultrasound devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the ultrasound devices and equipment industry. This ultrasound devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ultrasound systems devices and equipment market size will grow from $9.72 billion in 2022 to $10.23 billion in 2023 at a compound annual growth rate (CAGR) of 5.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The ultrasound systems devices and equipment market size is expected to grow from $12.06 billion in 2027 at a CAGR of 4.2%. Government and private funding in ultrasonic device manufacturing companies are driving the growth of the ultrasound systems device and equipment market. The investments by private firms as well government would provide adequate capital for the ultrasonic device manufacturing companies to conduct research and development and develop innovative and advanced ultrasound devices. For example, Chinese ultrasonic companies like Sonoscape, Mindray, and SIUI have benefitted from a government initiative to boost local manufacturers. Also, Private equity firm KKR decided to invest $35 million in Australia's ultrasound device maker Signostics Ltd. Hence, this funding would not only encourage innovative devices but boost the market as well. Strict approvals and regulations by government bodies such as US Food and Drug Administration (FDA) is hampering the growth of the Ultrasound system devices and equipment market. The manufacturers are required to comply with several regulations in the form of device quality check, labeling, premarket approval, device investigation, and reporting, apart from the regular registration process. Such excessive, strict, and rigid regulations are restraining the market's growth. Due to these stringent regulations, many manufacturers prefer to outsource the manufacturing to other countries where no such regulations are imposed. For example, FDA rejected the launch of EDAP TMS's latest High-Intensity Focused Ultrasound (HIFU) device stating safety concerns. The introduction of the 3D/4D Ultrasound devices is the latest trend that is going to change the landscape of ultrasound devices and the equipment market. The 3D/4D technology ultrasound device provides real-time enhanced imaging of the internal anatomy/fetus, also enabling real-time volume imagining. This technology can also help in performing complex surgeries. The 3D/4D ultrasound device would also feature improved image visualization power, shorten examination time and decrease strain injury during the surgery. For example, Toshiba's Aplio i900 Ultrasound machine makes use of the 3D/4D technology. The safety and effectiveness of ultrasound system devices and equipment is heavily monitored and regulated across the world. In November 2021, the Central Drugs Standard Control Organization (CDSCO), Indian regulator of drugs and medical devices, came up with a notification for the use of ultrasound equipment. From the date of release, ultrasound devices are notified as ‘drugs’ and it will be regulated as drugs. These stringent regulatory policies may impact the ultrasound system devices and equipment market in Canada, one of the fastest-growing markets. Major players in the ultrasound devices and equipment market are GE Healthcare, Siemens Healthineers, Philips Healthcare, Mindray Medical International Ltd., Fujifilm Holdings Corporation, Hitachi Ltd., Toshiba Corporation, Samsung Electronics, and Canon Medical Systems. Western Europe was the largest region in the global ultrasound devices and equipment market in 2022. North America was the second largest market in global ultrasound devices and equipment market. The regions covered in the ultrasound devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the ultrasound devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The ultrasound systems devices and equipment market consist of sales of diagnostic ultrasound systems (2d imaging systems, 3d & 4d imaging systems, Doppler imaging) and therapeutic ultrasound systems (high-intensity focused ultrasound, extracorporeal shockwave lithotripsy). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ultrasound systems devices and equipment market is segmented - 1) By Type: Diagnostic Ultrasound Systems, Therapeutic Ultrasound Systems 2) By End User: Hospitals, Diagnostic Imaging & Surgical Centers, Ambulatory surgical centers (ASCs), Clinics 3) By Product: A-Mode, B-Mode or 2D Mode, C-Mode, M-Mode, Doppler Mode, Pulse Inversion Mode, Harmonic Mode

Cancer diagnostic devices are used to diagnose the stage and cause of the condition by identifying the oncogenic proteins, and certain enzymes released by the tumor cells in patients. The main products in cancer diagnostics are companion diagnostics and molecular diagnostics. Molecular diagnostics is a laboratory method that is used to check for certain proteins, genes, or other molecules that may be a sign of cancer. The methods used in cancer diagnostics are biopsy, endoscopy, tumor biomarker tests, and imaging. The applications covered in cancer diagnostics are cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others that are used by end-users such as cancer research institutes, diagnostic laboratories, hospitals, and others. The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cancer diagnostics market size will grow from $19.18 billion in 2022 to $21.38 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cancer diagnostics market size is expected to grow to $33.13 billion in 2027 at a CAGR of 11.6%. A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers are leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030. Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older. The AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%. The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into the Class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, post market surveillance, and labeling requirements associated with their usage. For instance, the labeling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings, and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices. Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd., GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Illumina, Elekta AB, and C.R. BardInc. North America was the largest region in the cancer diagnostics market in 2022. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the global cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cancer diagnostics market is segmented - 1) By Products: Companion Diagnostics, Molecular Diagnostics 2) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users 3) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging 4) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications

Cervical cancer is a type of squamous cell carcinoma that occurs in the cervix (the lower part of the uterus). The cervix cancer diagnostic devices are used to diagnose cancer that occurs in the cervix. The main types of cervical cancer diagnostics are pap smear tests, HPV tests, colposcopy, biopsy, endocervical curettage, and other diagnostic tests. The pap smear test is the process of testing for cervical cancer in women. The age groups involved are those under 21, those between 21 and 29, those between 30 and 65, and those over 65. The end-users involved are hospitals, specialty clinics, cancer and radiation therapy centers, and diagnostic centers. The cervical cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cervical cancer diagnostics market statistics, including cervical cancer diagnostics industry global market size, regional shares, competitors with a cervical cancer diagnostics market share, detailed cervical cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer diagnostics industry. This cervical cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cervical cancer diagnostics market grew from $8.29 billion in 2022 to $8.86 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cervical cancer diagnostics market is expected to grow from $11.03 billion in 2027 at a CAGR of 5.6%. The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. For instance, in August 2020, the World Health Assembly adopted a global strategy to accept cervical cancer as a global challenge and to develop a global strategy to eliminate cervical cancer. First step of this strategy is promoting diagnosis. The rising adoption of cervical cancer diagnostic tests and emphasis on early diagnosis propels the market. The increased use of HPV vaccination is anticipated to hinder the cervical cancer diagnostics market. According to the World Health Organization, the 2 HPV types (16 and 18) cause 70% of cervical cancers and pre-cancerous cervical lesions, thereby giving human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical pre-cancerous lesions that may develop into cervical cancers. The study published in Cancer Epidemiology, Biomarkers & Prevention, in September 2022, the Union Minister of India announced the launch of India’s first indigenously developed vaccine for cervical cancer. Furthermore, according to National Cancer Institute, one dose of cancer is sufficient for reducing the risk of cervical cancer by a large margin. Therefore, the increased use of HPV vaccination is predicted to hinder the cervical cancer diagnostics market. The increased adoption of HPV home testing kits is expected to be the new trend in the market. The home-based HPV testing kits help women in collecting samples and getting the results conveniently on their own without going to the lab for screening. Therefore, companies are focusing on providing convenience to patients. For instance, in September 2022, Mylab Discovery Solutions launched the ‘PathoDetectTM HPV PCR detection Kit (Type 16/18). The new product is a home testing kit for detection of HPV type 16 and type 18. In May 2020, the USA-based firm, Becton, Dickinson & Co., a manufacturer and seller of medical devices, instrument systems, and reagents, announced the acquisition of San Diego biomedical business CareFusion for $12.2 billion. The acquisition is expected to improve the quality of patient care and reduce health care costs by identifying the needs in hospitals, hospital pharmacies, and alternate sites of care. Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens Healthineers AG, ZiliCo., and Guided Therapeutics. North America was the largest region in the cervical cancer diagnostics market in 2022. Asia-Pacific was the second largest region in the global cervical cancer diagnostics market. The regions covered in the global cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cervical cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cervical cancer diagnostics market consists of sales of analyzer, reagents, and others that are used for the diagnosis of cervical cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cervical cancer diagnostics market is segmented - 1) By Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy, and Endocervical Curettage, Other Diagnostic Tests 2) By End User: Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres, Diagnostic Centres 3) By Age Group: Below 21, Age between 21 to 29, Age between 30 to 65, Above 65

Interventional radiology is a field of radiology that uses medical imaging to guide minimally invasive surgical procedures for diagnosis and treatment. The main types of products in the interventional radiology market are MRI, ultrasound imaging, CT scanners, angiography systems, fluoroscopy systems, biopsy devices, and others. MRI interventional radiology devices scan produce detailed images of the organs and tissues in the body. The different procedures include angioplasty, angiography, biopsy and drainage, embolization, thrombolysis, vertebroplasty, nephrostomy, and others and are used in cardiology, urology and nephrology, oncology, gastroenterology, and others. The interventional radiology market research report is one of a series of new reports from The Business Research Company that provides interventional radiology market statistics, including interventional radiology industry global market size, regional shares, competitors with a interventional radiology market share, detailed interventional radiology market segments, market trends and opportunities, and any further data you may need to thrive in the interventional radiology industry. This interventional radiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global interventional radiology market size grew from $20.68 billion in 2022 to $22.57 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interventional radiology market size is expected to grow to $31.77 billion in 2027 at a CAGR of 8.9%. The increase in prevalence of cancer is expected to drive the growth of the interventional radiology market in the coming years. Cancer is a global health problem and is the second leading cause of death in the United States. Interventional radiology uses a variety of techniques such as ablation, embolization, and irreversible electroporation (IRE) to treat cancer and cardiovascular disorders. For instance, according to the American Cancer Society, there were 1,806,590 new cancer cases and 606,520 cancer deaths in 2020 in the USA. New cases of leukemia, lymphoma, and myeloma are expected to account for 9.9% of the estimated 178,520 new cases diagnosed in the USA in 2020 and in approximately every 3 minutes one person in the US is diagnosed with blood cancer. Hence, the increasing prevalence of cancer drives the growth of the interventional radiology market. Artificial Intelligence is a key trend gaining popularity in the interventional radiology market. Companies operating in the interventional radiology sector continuously focus on introducing new technologies to survive in the interventional radiology market. For instance, in September 2012, GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging, launched AI-powered Cath lab - Optima IGS 320in India. It uses GE's AutoRight technology, which automates image and dose parameter optimization in real-time using AI so that doctors may concentrate their attention and clinical experience on patients. The Optima IGS 320's next-generation interventional imaging software offers clinical adaptability to more precisely direct complex non-invasive procedures. By using AutoRight to automate the often difficult process, interventionists are given less work to do and may pay more attention to the process. In August 2020, Seimens Healthineers, a Germany-based medical device manufacturer specializing in medical imaging, laboratory diagnostics, point of care diagnostics, and other segments acquired Varian for $16.4 billion. With this acquisition, Seimens plans to expand its cancer devices portfolio used for screening and treating different cancers. Varian is a UK-based medical technology company that provides products for radio-oncology treatments. Major players in the interventional radiology market are Carestream Health, Siemens AG, Koninklijke Philips N.V., General Electric Company, Hitachi Medical Corporation, Canon Medical Systems Corporation, Toshiba Medical Systems, Medtronic plc, Shimadzu Corporation, Fujifilm Holdings Corp., Hologic Inc., Agfa-Gevert N.V., Esaote S.P.A., and Samsung Medison. North America was the largest region in the interventional radiology market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interventional radiology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the interventional radiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The interventional radiology market consists of sales of atherectomy systems, cancer therapies, and balloon catheters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global interventional radiology market is segmented - 1) By Product: MRI, Ultrasound Imaging, CT Scanners, Angiography Systems, Fluoroscopy Systems, Biopsy Devices, Other Products 2) By Procedure: Angioplasty, Angiography, Biopsy And Drainage, Embolization, Thrombolysis, Vertebroplasty, Nephrostomy, Other Procedures 3) By Application: Oncology, Cardiology, Urology And Nephrology, Gastroenterology, Other Applications

Gastrointestinal devices are used for the diagnosis and treatment of medical conditions related to the digestive system or the gastrointestinal tract. The main product types of gastrointestinal devices are GI videoscopes, biopsy devices, endoscopic retrograde cholangiopancreatography devices (ERCP), capsule endoscopy, endoscopic ultrasound, endoscopic mucosal resection (EMR), hemostasis devices, and others. Endoscopic retrograde cholangiopancreatography, or ERCP refers to a process of diagnosing and treating problems in the liver, gallbladder, bile ducts, and pancreas. The various sales channels are online retailing, medical stores, and brand outlets. These are used in hospitals, clinics, dialysis centres, and ambulatory surgical centres. The gastrointestinal devices market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal devices market statistics, including gastrointestinal devices industry global market size, regional shares, competitors with a gastrointestinal devices market share, detailed gastrointestinal devices market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal devices industry. The gastrointestinal devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global gastrointestinal devices market grew from $10.05 billion in 2022 to $10.61 billion in 2023 at a compound annual growth rate (CAGR) of 5.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gastrointestinal devices market is expected to grow from $13.7 billion in 2027 at a CAGR of 6.6%. The increasing prevalence of gastrointestinal diseases contributed to the growth of the gastrointestinal devices market. Gastrointestinal diseases include irritable bowel syndrome, hemorrhoids, perianal abscesses, colon polyps, and cancer, among others. According to the Endoscopy Centre, every year, 62 million Americans are diagnosed with any of the digestive disease, and 2% to 6% or an estimated three lakhs to 5 lakhs Americans suffer from inflammatory bowel disease (IBD). According to the American College of Gastroenterology estimates, 10-15% of the adult population in the USA suffer from irritable bowel syndrome (IBS) symptoms. The increased prevalence of gastrointestinal diseases increased the demand for gastrointestinal devices to treat patients, thereby driving the market growth. High healthcare costs for treating gastrointestinal disease restrain the gastrointestinal devices market. According to the NEJM Journal Watch, a sister publication of the New England Journal of Medicine, the overall healthcare expenditure for the gastrointestinal disease is around $136 billion annually, which is more than heart disease healthcare expenditure ($113 billion), trauma expenditure ($103 billion), mental health expenditure ($99 billion), indicating the high expenses involved in treating gastrointestinal disease. Moreover, a database analysis by American Gastroenterological Association states that patients with inflammatory bowel diseases (IBDs), chronic liver diseases (CLDs), functional gastrointestinal disorders (FGIDs), gastrointestinal hemorrhage are hospitalized at least once and are high-need and high-cost patients contributing disproportionately to hospitalization costs. In this context, they are the ones who are accessing inpatient services and need immense care due to functional limitations increasing the expenditure. The high healthcare expenditure for gastrointestinal disease forces the majority population to refrain from receiving treatment in non-emergency cases, which negatively impacts the growth of the gastrointestinal devices market. Single-use disposable endcap of duodenoscope is increasingly being used to prevent contamination during endoscopic retrograde cholangiopancreatography (ERCP) procedures. Single-use disposable cap controls the infection and preserves the duodenoscope optics. The USFDA recommended that hospitals and clinics shift from reusable duodenoscopes to disposable parts duodenoscopes. The USFDA also approved the duodenoscope model featuring the disposable parts such as the Olympus TJF-Q190V Duodenoscope in January 2020 and Ambu® aScope™ Duodenoscope in July 2020. Olympus TJF-Q190V duodenoscope is used to perform the ERCP procedure with less risk of contamination due to the disposable distal endcap. For instance, in 2020, Olympus Corporation has announced the acquisition of Arc Medical Design Limited (Arc Medical Design), a subsidiary of Norgine B.V. This acquisition helps Olympus’ commitment to enlarging its offering in gastrointestinal therapeutic devices and the improvement of advanced colonoscopy tools. Norgine is a European-based specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Major players in the gastrointestinal devices market are Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson & Johnson, Olympus, Cook Group, Becton, Dickinson, and Company, and B. Braun Melsungen. North America was the largest region in the gastrointestinal devices market in 2022. Asia-Pacific was the second largest region in the global gastrointestinal devices market report. The regions covered in the global gastrointestinal devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gastrointestinal devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The gastrointestinal devices market consists of sales of instruments such as gastroscope, an enteroscope, and an ultrasound endoscope. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global gastrointestinal devices market is segmented - 1) By Product Type: GI Videoscopes, Biopsy Devices, Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), Capsule Endoscopy, Endoscopic Ultrasound, Endoscopic Mucosal Resection (EMR), Hemostasis Devices, Other Product Types 2) By End Users: Hospitals, Clinics & Dialysis Centers, Ambulatory Surgical Center 3) By Sales Channel: Online Retailing, Medical Stores & Brand Outlet

Breast cancer is characterised by uncontrolled growth of cells in the breast, causing lumps. The breast cancer diagnostic devices are used to diagnose cancer that occurs in the breasts. The main types of breast cancer diagnostics are imaging, biopsy, genomic tests, blood tests, and others. A biopsy is the process of removing a piece of tissue or a sample of cells from the body so that it can be tested in a laboratory. The technologies involved is fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), and other technologies. The cancer types involved are BRCA breast cancer, ER and PR breast cancer, her type 2-breast cancer, EGFR mutation test breast cancer, and others. The diagnostic types involved are ionising breast imaging technologies and non-ionizing imaging technologies. The end-users involved are hospitals and clinics, cancer research centers, diagnostic laboratories, and ambulatory surgical centers. The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global breast cancer diagnostics market grew from $4.06 billion in 2022 to $4.4 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The breast cancer diagnostics market is expected to grow from $5.86 billion in 2027 at a CAGR of 7.4%. The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for the breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. According to the World Health Organization (WHO), around 2.3 million women were diagnosed with breast cancer and 685,000 people died of breast cancer in 2020. Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market. The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer. The cost of diagnosis for breast cancer typically rose with the initiation of the diagnostic stage of the disease. According to HealthMatch, in 2020, the total cost of breast cancer treatment ranged between $20,000 and $100,000. The diagnosis alone ranged between $151 and $751 in various regions. Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market. Technological advancement is a key trend in the breast cancer diagnostics market. Several new techniques have been developed which could be used in the diagnosis and treatment of breast cancer. The 3D mammography, also known as breast tomosynthesis, takes photographs around the breast from various angles and translates them into a 3-D model. In September 2022, Niramai, an Indian Health-Tech company, launched an innovative solution called Thermalytix. It is a automated breast cancer screening and diagnostic tool which combines thermal imaging and AI. In January 2021, Hologic, a US-based women’s health medtech company, acquired Somatex Medical for $64 million. The acquisition would support Hologic’s strategy to provide comprehensive solutions for breast health care. Somatex is a German-based provider of Breast cancer diagnostic services. Major players in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., and C.R. Bard Inc. North America was the largest region in the breast cancer diagnostics market in 2022. Asia-Pacific was the second largest region in the global breast cancer diagnostics market. The regions covered in the global breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global breast cancer diagnostics market is segmented - 1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types 2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies 3) By Cancer Type: BRCA Breast Cancer, ER & PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types 4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies 5) By End Users: Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers